PDCD1 and breast cancer: The combination of niraparib and anti-PD-1 therapy was next evaluated in the breast cancer syngeneic transplant MMTV-LPA1-T22 model established by the sequential orthotopic transplantation of tumors originating from autotaxin (ATX)-lysophosphatidic acid receptor transgenic mice40,41.